Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Donald Harvey

Showing results (1-10 of 144) with videos related to

Pageof 15
Sort By:
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|March 25, 2010
Myelodysplastic syndromes and the role of iron overloadR Donald Harvey
Pharmacotherapy|October 19, 2005
Intravenous immunoglobulin therapy: the process, the product, the patient, and the pocketbook. IntroductionR Donald Harvey
Journal of Oncology Practice|May 13, 2016
Calcium and Cancer: Of Evil Humors and Innocent BystandersR Donald Harvey
Journal of the National Cancer Institute|March 15, 2023
The earlier the better? Or better late than never? Dose optimization in oncologyR Donald Harvey
Journal of Oncology Practice|September 13, 2017
Science of BiosimilarsR Donald Harvey
Clinical Advances in Hematology & Oncology : H&O|November 17, 2020
Pack-splitting to improve cost-effectiveness of oral agents in oncologyR Donald Harvey
Clinical Pharmacology : Advances and Applications|May 24, 2014
Incidence and management of adverse events in patients with relapsed and/or refractory multiple myeloma receiving single-agent carfilzomibR Donald Harvey
Journal of Oncology Practice|February 15, 2019
Managing Drug Interactions With Oral Anticancer Agents: Signals, Noise, and EchoesR Donald Harvey
Pharmacotherapy|October 19, 2005
The patient: Emerging clinical applications of intravenous immunoglobulinR Donald Harvey
Future Oncology (London, England)|November 29, 2007
PI3 kinase/AKT pathway as a therapeutic target in multiple myelomaR Donald Harvey, Sagar Lonial
Pageof 15

Showing results (1-10 of 144) with videos related to

Sort By:
Pageof 15
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|March 25, 2010
Myelodysplastic syndromes and the role of iron overloadR Donald Harvey
Pharmacotherapy|October 19, 2005
Intravenous immunoglobulin therapy: the process, the product, the patient, and the pocketbook. IntroductionR Donald Harvey
Journal of Oncology Practice|May 13, 2016
Calcium and Cancer: Of Evil Humors and Innocent BystandersR Donald Harvey
Journal of the National Cancer Institute|March 15, 2023
The earlier the better? Or better late than never? Dose optimization in oncologyR Donald Harvey
Journal of Oncology Practice|September 13, 2017
Science of BiosimilarsR Donald Harvey
Clinical Advances in Hematology & Oncology : H&O|November 17, 2020
Pack-splitting to improve cost-effectiveness of oral agents in oncologyR Donald Harvey
Clinical Pharmacology : Advances and Applications|May 24, 2014
Incidence and management of adverse events in patients with relapsed and/or refractory multiple myeloma receiving single-agent carfilzomibR Donald Harvey
Journal of Oncology Practice|February 15, 2019
Managing Drug Interactions With Oral Anticancer Agents: Signals, Noise, and EchoesR Donald Harvey
Pharmacotherapy|October 19, 2005
The patient: Emerging clinical applications of intravenous immunoglobulinR Donald Harvey
Future Oncology (London, England)|November 29, 2007
PI3 kinase/AKT pathway as a therapeutic target in multiple myelomaR Donald Harvey, Sagar Lonial
Pageof 15